文献速递淋巴瘤造血干细胞移植与细胞治疗

阿基仑赛治疗大B细胞淋巴瘤中预防性糖皮质激素的应用

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
PubMed 文献 · Br J Haematol · 2021-07-22

ZUMA-1研究第6队列探讨预防性糖皮质激素及早期干预对阿基仑赛治疗难治性大B细胞淋巴瘤的安全性影响。

要点

  • 预防性地塞米松(10mg,第0-2天)联合早期干预可避免3级及以上CRS。
  • 3级及以上神经事件发生率低(13%),任何级别神经事件为58%。

核心结论

  • 预防性糖皮质激素及早期糖皮质激素和/或托珠单抗干预未出现3级及以上CRS,3级及以上神经事件发生率低,且缓解率高。

研究设计与样本

  • 患者接受预处理化疗(第-5至-3天),2×10^6 CAR-T细胞/kg(第0天),以及每日口服地塞米松10mg(第0天至第2天)。

主要发现

  • 细胞因子释放综合征发生率为80%,所有级别均≤2级。
  • 任何级别和3级及以上神经事件发生率分别为58%和13%。

临床怎么用

  • 在阿基仑赛治疗大B细胞淋巴瘤时,可考虑预防性使用地塞米松并早期干预以降低CRS和神经事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ZUMA-1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous CD19-directed chimaeric antigen receptor (CAR)-T cell therapy, in refractory large B-cell lymphoma. To reduce treatment-related toxicity, several exploratory safety management cohorts were added to ZUMA-1. Specifically, cohort 6 investigated management of cytokine release syndrome (CRS) and neurologic events (NEs) with prophylactic corticosteroids and earlier corticosteroid and tocilizumab intervention. CRS and NE incidence and severity were primary end-points. Following leukapheresis, patients could receive optional bridging therapy per investigator discretion. All patients received conditioning chemotherapy (days -5 through -3), 2 × 106 CAR-T cells/kg (day 0) and once-daily oral dexamethasone [10 mg, day 0 (before axi-cel) through day 2]. Forty patients received axi-cel. CRS occurred in 80% of patients (all grade ≤2). Any grade and grade 3 or higher NEs occurred in 58% and 13% of patients respectively. Sixty-eight per cent of patients did not experience CRS or NEs within 72 h of axi-cel. With a median follow-up of 8·9 months, objective and complete response rates were 95% and 80% respectively. Overall, prophylactic corticosteroids and earlier corticosteroid and/or tocilizumab intervention resulted in no grade 3 or higher CRS, a low rate of grade 3 or higher NEs and high response rates in this study population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Oluwole OO, Bouabdallah K, Muñoz J, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021. PMID: 34296427. doi:10.1111/bjh.17527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。